Eflornithine

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2565 publications

Eflornithine for neuroblastoma.

Eflornithine for neuroblastoma.

Journal: Australian prescriber

Published: June 18, 2026

Anti-Polyamine Therapy Restrains Kidney Cyst Growth in an Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease.

Anti-Polyamine Therapy Restrains Kidney Cyst Growth in an Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2026

Targeted Therapies in Neuroblastoma: A History and a View to the Future.

Targeted Therapies in Neuroblastoma: A History and a View to the Future.

Journal: Cancers

Published: April 07, 2026

New insights for an old drug: difluoromethylornithine boosts the trypanocidal action of benznidazole on Trypanosoma cruzi in vitro and in vivo.

New insights for an old drug: difluoromethylornithine boosts the trypanocidal action of benznidazole on Trypanosoma cruzi in vitro and in vivo.

Journal: Frontiers in cellular and infection microbiology

Published: January 22, 2026

Chemoprevention of Keratinocyte Carcinomas and Actinic Keratoses in Immunocompetent Patients: A Systematic Review.

Chemoprevention of Keratinocyte Carcinomas and Actinic Keratoses in Immunocompetent Patients: A Systematic Review.

Journal: Clinical and experimental dermatology

Published: December 11, 2025

Alpha-difluoromethylornithine suppresses angiogenesis via the FLI1-CLEC14A-VEGFC pathway in retinal endothelial cells.

Alpha-difluoromethylornithine suppresses angiogenesis via the FLI1-CLEC14A-VEGFC pathway in retinal endothelial cells.

Journal: Biochemical and biophysical research communications

Published: December 11, 2025

Polyamine Metabolism as a Metabolic Vulnerability in Prostate Cancer Treated with Supraphysiological Androgens.

Polyamine Metabolism as a Metabolic Vulnerability in Prostate Cancer Treated with Supraphysiological Androgens.

Journal: Cancer research

Published: December 05, 2025

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 01, 2025

Single-cell Sequencing and Machine Learning Identify Amino Acid Metabolism-related Biomarkers and Regulatory Mechanisms in Diabetic Foot Ulcers.

Single-cell Sequencing and Machine Learning Identify Amino Acid Metabolism-related Biomarkers and Regulatory Mechanisms in Diabetic Foot Ulcers.

Journal: Endocrine, metabolic & immune disorders drug targets

Published: December 01, 2025

Conformational analysis of difluoromethylornithine: factors influencing its gas-phase and bioactive conformations.

Conformational analysis of difluoromethylornithine: factors influencing its gas-phase and bioactive conformations.

Journal: Beilstein journal of organic chemistry

Published: November 03, 2025

Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-blinded, Randomized Clinical Trial.

Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-blinded, Randomized Clinical Trial.

Journal: Cancer prevention research (Philadelphia, Pa.)

Published: September 17, 2025

Combination of Intense Pulsed Light and Topical Eflornithine Therapy Versus Intense Pulsed Light Alone in the Treatment of Idiopathic Facial Hirsutism: A Randomized Controlled Trial.

Combination of Intense Pulsed Light and Topical Eflornithine Therapy Versus Intense Pulsed Light Alone in the Treatment of Idiopathic Facial Hirsutism: A Randomized Controlled Trial.

Journal: Cureus

Published: August 18, 2025

Showing 1-12 of 2,565

Last Updated: 06/30/2026